Merck (MRK) Q1 2025: Pipeline Expansion and Supply Chain Realignment Anchor Long-Term Growth Strategy
Merck’s first quarter 2025 results reflected resilient demand for oncology and new launches, offset by vaccine headwinds in China and currency drag. The company is doubling down on pipeline innovation and U.S.-centric supply chain investments to buffer tariff risk and prepare for Keytruda’s looming loss of exclusivity. Strategic capital allocation and business development remain central as Merck navigates a shifting global regulatory and competitive landscape.
Summary
- Oncology and New Launches Drive Revenue: Q1 revenue of $15.5B was flat YoY, with 8% underlying growth excluding China Gardasil and FX impact, fueled by Keytruda, WinRivair, and Capvaxif.
- Vaccine Headwinds in China: Gardasil sales dropped 40% due to channel inventory and weak demand in China, partially offset by robust international growth.
- Supply Chain and Tariff Mitigation: Over $21B committed to U.S. manufacturing since 2018 positions Merck to manage tariff exposure and regulatory shifts.
- Pipeline and Business Development Emphasis: Late-stage pipeline now includes 20+ potential blockbusters, with business development and innovation prioritized to offset Keytruda LOE risk.
Performance Analysis
Merck delivered Q1 revenue of $15.5B, flat year-over-year, but underlying growth was 8% when excluding the $1.1B China Gardasil decline and currency headwinds. Keytruda, Merck’s flagship immuno-oncology therapy, grew 6% to $7.2B (46% of total revenue), with broad-based demand in earlier-stage and metastatic cancers. New launches, WinRivair, pulmonary arterial hypertension therapy, and Capvaxif, pneumococcal vaccine, contributed meaningfully, signaling traction for Merck’s next wave of growth drivers.
Gardasil, HPV vaccine, saw a 40% sales drop driven by China inventory and demand softness, even as ex-China sales grew double digits. Animal health posted 10% growth, while gross margin improved to 82.2% on favorable mix. Operating expenses were disciplined, with increased R&D and pipeline investment. EPS was $2.22, with guidance for full-year EPS of $8.82–$8.97, including a $200M tariff cost offset by FX tailwinds.
- Oncology Resilience: Keytruda remains the primary earnings engine, but dependency persists as it approaches LOE in 2028.
- Vaccine Volatility: Gardasil’s China drag is a material headwind for 2025, with Japan’s catch-up program ending and global growth moderating.
- Pipeline Contribution: WinRivair and Capvaxif launches are gaining momentum, validating Merck’s pipeline investment thesis.
Underlying business health is robust, but headline numbers mask significant product and geographic volatility. The company’s ability to offset legacy declines with new launches will be tested as Keytruda’s exclusivity wanes.
Executive Commentary
"Our performance was in line with our expectations with revenue of $15.5 billion, reflecting strength in oncology, animal health, and increasingly meaningful contributions from the continued strong launches of WinRivair and Capvaxif... We remain confident in our outlook for improved growth in the second half of the year."
Rob Davis, Chairman and Chief Executive Officer
"Total company revenues were $15.5 billion, a decrease of 2% or an increase of 1%, excluding the impact of foreign exchange. As expected, results were impacted by a decline in sales of Gardasil in China of approximately $1.1 billion... Excluding these sales and the impact from foreign exchange, global growth was 8%, primarily driven by new products, WinRivair and Capvaxif, as well as strength in oncology and animal health."
Caroline Litchfield, Chief Financial Officer
"Since 2021, we've nearly tripled our late phase pipeline through both the advancement of internally discovered compounds, as well as the completion of numerous important business development transactions... Together, our efforts have resulted in an expanded late phase pipeline, comprising programs having potential commercial opportunity of over $50 billion by the mid 2030s."
Rob Davis, Chairman and Chief Executive Officer
Strategic Positioning
1. Oncology Leadership and Keytruda Transition
Keytruda, PD-1 immunotherapy, remains Merck’s core value driver, but the company is acutely aware of the 2028 loss of exclusivity (LOE) risk. Management is emphasizing the breadth of Keytruda’s indications (41 approvals across 18 tumor types) and is aggressively expanding into earlier-stage settings, where competitive threats are less acute. The development of subcutaneous formulations and new combinations is designed to extend lifecycle and defend share as biosimilar threats emerge.
2. Pipeline Diversification and Launch Execution
WinRivair and Capvaxif launches are central to Merck’s narrative of pipeline-driven renewal. WinRivair’s robust Phase 3 data and rapid uptake position it as a potential blockbuster in pulmonary arterial hypertension. Capvaxif is gaining regulatory traction globally, with recent EU approval, and is expected to drive adult pneumococcal franchise growth. The pipeline now includes 20+ late-stage assets, with management targeting over $50B in potential commercial opportunity by the mid-2030s.
3. Supply Chain Localization and Tariff Readiness
Merck is proactively realigning its global supply chain, with over $21B invested or committed to U.S. manufacturing since 2018. This “U.S. for U.S.” approach is designed to insulate the company from tariff shocks and regulatory volatility, especially as U.S.-China trade tensions escalate. Inventory management and external manufacturing contracts provide near-term flexibility, while long-term capital projects will anchor production domestically.
4. Business Development and External Innovation
Acquisitions and licensing remain a strategic priority, with a focus on science-driven, value-accretive deals across oncology, cardiometabolic, ophthalmology, and immunology. Management is balancing first-in-class and best-in-class assets, with an eye toward both pipeline breadth and combinatorial innovation. The external environment is complex, with seller price expectations often misaligned with market realities, but Merck remains active and expects additional transactions.
5. Capital Allocation and Shareholder Returns
Merck’s capital allocation remains disciplined, prioritizing internal investment, pipeline advancement, and business development. Share repurchases rose to $1.2B in Q1 (matching all of 2024), but management remains committed to the dividend and reinvestment in growth drivers. Productivity initiatives and cost controls are being pursued to ensure margin resilience as the portfolio mix shifts.
Key Considerations
Merck’s Q1 2025 results underscore a business in transition, balancing mature franchise risks with new product momentum and aggressive pipeline expansion.
Key Considerations:
- Gardasil China Drag: Inventory and demand pressures in China are a major 2025 headwind, with limited near-term recovery expected.
- Keytruda LOE Looms: The company’s future hinges on successful pipeline launches and lifecycle management to offset the expected Keytruda revenue cliff post-2028.
- Tariff and Regulatory Volatility: U.S.-centric supply chain investments provide a buffer, but ongoing trade and pricing policy risks require continued vigilance.
- Pipeline Execution: Timely data readouts, regulatory approvals, and launch execution for WinRivair, Capvaxif, and pipeline assets are critical to sustaining growth.
- Business Development Discipline: The ability to secure accretive deals in a competitive and uncertain environment will shape long-term positioning.
Risks
Key risks include: an accelerated Keytruda revenue decline as biosimilar competition nears, further vaccine demand weakness in China, and execution risk around pipeline launches. Tariff escalation or regulatory changes could impact cost structure and market access. External business development remains subject to valuation gaps and integration challenges, while global pricing pressure and reference pricing proposals could erode U.S. profitability.
Forward Outlook
For Q2 and full-year 2025, Merck guided to:
- Revenue of $64.1–$65.1B (1–3% growth ex-FX)
- Gross margin of ~82% (includes $200M in tariffs)
- EPS of $8.82–$8.97 (impacted by FX and one-time charges)
Management expects second-half growth acceleration as Keytruda inventory timing normalizes and new launches ramp. Gardasil growth outside China will moderate, with Japan catch-up cohort ending. Guidance does not assume further major business development or additional tariffs. Near-term pipeline milestones in oncology, cardiometabolic, and HIV are key watchpoints.
Takeaways
Merck’s Q1 2025 results highlight a business at a critical inflection, with strong execution in core oncology and new launches buffering vaccine volatility and looming patent cliffs.
- New Launches Gaining Traction: WinRivair and Capvaxif are emerging as credible growth drivers, validating pipeline investment and launch capabilities.
- Proactive Supply Chain Strategy: U.S. manufacturing investments and inventory management position Merck to weather tariff risk and regulatory shifts.
- Pipeline and BD Are Central: Ongoing pipeline expansion and disciplined business development will determine Merck’s post-Keytruda trajectory, with execution risk front and center.
Conclusion
Merck is executing a multi-pronged strategy to bridge its legacy-to-growth transition, with pipeline launches, supply chain realignment, and business development at the forefront. The next 12–24 months will be decisive as the company seeks to offset Keytruda’s eventual decline and navigate global policy volatility.
Read-Through
Merck’s results and strategic pivots reflect sector-wide pressures—from U.S.-China trade friction and global supply chain reconfiguration to the imperative of pipeline-driven renewal as legacy blockbusters near LOE. The focus on U.S. manufacturing and inventory resilience is a template for peers facing similar tariff and regulatory risk. Vaccine volatility, especially in China, signals that global demand assumptions must be stress-tested. The emphasis on late-stage pipeline breadth and business development discipline is a clear read-through for large-cap pharma, where the ability to execute on both internal and external innovation will separate future leaders from laggards.